Clinical Microbiology, MTC, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Clin Microbiol Infect. 2011 Apr;17(4):552-6. doi: 10.1111/j.1469-0691.2010.03294.x.
Enterobacteriaceae producing carbapenemases, such as KPC or metallo-β-lactamases (MBLs), have emerged on several continents. Phenotypic tests are urgently needed for their rapid and accurate detection. A novel carbapenemase detection test, comprising a meropenem disk, and meropenem disks supplemented with 730 μg of EDTA, 1000 μg of dipicolinic acid (DPA), 600 μg of aminophenylboronic acid (APBA), or 750 μg of cloxacillin, was evaluated against Klebsiella pneumoniae isolates with KPC (n = 34), VIM (n = 21), IMP (n = 4) or OXA-48 (n = 9) carbapenemases, and carbapenem-resistant Enterobacteriaceae with porin loss in combination with an extended-spectrum β-lactamase (ESBL) (n = 9) or AmpC hyperproduction (n = 5). Commercially available diagnostics tablets from Rosco containing meropenem and the same inhibitors as described above (except EDTA) were also evaluated. An increased meropenem inhibition zone was sought in the presence of each added β-lactamase inhibitor. APBA had excellent sensitivity for detecting K. pneumoniae with KPC enzymes. Isolates with combined AmpC hyperproduction and porin loss were also positive in the APBA test but, unlike KPC producers, showed cloxacillin synergy. Both DPA and EDTA had excellent sensitivity for detection of MBL-producing K. pneumoniae. However, EDTA showed poor specificity, with positive results noted for 1/9 ESBL-producing isolates, for 4/34 KPC-producing isolates, and for 4/9 OXA-48-producing isolates, whereas all of these were negative when DPA was used. The in-house test distinguished accurately between several different mechanisms mediating reduced susceptibility to carbapenems in Enterobacteriaceae. The commercial combination tablets from Rosco performed similarly to the in-house test, with the exception of one false-positive MBL result and one false-positive KPC result among the OXA-48 producers.
肠杆菌科产生碳青霉烯酶,如 KPC 或金属β-内酰胺酶(MBLs),已在各大洲出现。迫切需要进行表型检测以快速准确地检测。一种新的碳青霉烯酶检测试验,包括美罗培南纸片和补充 730μg EDTA、1000μg 二吡啶酸(DPA)、600μg 氨苯基硼酸(APBA)或 750μg 氯唑西林的美罗培南纸片,用于检测产 KPC(n=34)、VIM(n=21)、IMP(n=4)或 OXA-48(n=9)碳青霉烯酶的肺炎克雷伯菌分离株以及同时具有孔蛋白缺失和超广谱β-内酰胺酶(ESBL)(n=9)或 AmpC 过度产生(n=5)的耐碳青霉烯肠杆菌。还评估了含有美罗培南和上述相同抑制剂(除 EDTA 外)的 Rosco 市售诊断片剂。在存在每种添加的β-内酰胺酶抑制剂的情况下,寻找增加的美罗培南抑制区。APBA 对检测产 KPC 酶的肺炎克雷伯菌具有出色的敏感性。同时具有 AmpC 过度产生和孔蛋白缺失的分离株在 APBA 试验中也呈阳性,但与 KPC 产生菌不同,表现出氯唑西林协同作用。DPA 和 EDTA 对产 MBL 的肺炎克雷伯菌的检测均具有出色的敏感性。然而,EDTA 的特异性较差,在 1/9 产 ESBL 的分离株、4/34 产 KPC 的分离株和 4/9 产 OXA-48 的分离株中均出现阳性结果,而当使用 DPA 时,所有这些结果均为阴性。内部试验准确地区分了肠杆菌科对碳青霉烯类药物敏感性降低的几种不同机制。罗氏的商业组合片剂与内部试验表现相似,除了在产 OXA-48 的分离株中出现一个假阳性 MBL 结果和一个假阳性 KPC 结果外。